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Objectives The purpose of this study was to determine the relevance of S100A12 expression to human thoracic aortic an-
eurysms and type A thoracic aortic aneurysm dissection and to study mechanisms of S100A12-mediated dys-
function of aortic smooth muscle cells.
Background Transgenic expression of proinflammatory S100A12 protein in murine aortic smooth muscle causes thoracic
aneurysm in genetically modified mice.
Methods Immunohistochemistry of aortic tissue (n  50) for S100A12, myeloperoxidase, and caspase 3 was examined
and S100A12-mediated pathways were studied in cultured primary aortic smooth muscle cells.
Results We found S100A12 protein expressed in all cases of acute thoracic aortic aneurysm dissection and in approxi-
mately 25% of clinically stable thoracic aortic aneurysm cases. S100A12 tissue expression was associated with
increased length of stay in patients undergoing elective surgical repair for thoracic aortic aneurysm, despite sim-
ilar preoperative risk as determined by European System for Cardiac Operative Risk Evaluation. Reduction of
S100A12 expression in human aortic smooth muscle cells using small hairpin RNA attenuates gene and protein
expression of many inflammatory- and apoptosis-regulating factors. Moreover, genetic ablation of the receptor
for S100A12, receptor for advanced glycation end products (RAGE), in murine aortic smooth muscle cells abol-
ished cytokine-augmented activation of caspase 3 and smooth muscle cell apoptosis in S100A12-expressing
cells.
Conclusions S100A12 is enriched in human thoracic aortic aneurysms and dissections. Reduction of S100A12 or genetic
ablation of its cell surface receptor, the receptor for advanced glycation end products (RAGE), in aortic smooth
muscle resulted in decreased activation of caspase 3 and in reduced apoptosis. By establishing a link between
S100A12 expression and apoptosis of aortic smooth muscle cells, this study identifies novel S100A12 signaling path-
ways and indicates that S100A12 may be a useful molecular marker and possible target for treatment for human
aortic diseases. (J Am Coll Cardiol 2012;60:775–85) © 2012 by the America n College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.027f
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mThoracic aortic aneurysms (TAA) encompass a broad range
of degenerative, genetic, structural, and acquired disease
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accepted April 16, 2012.states and can be complicated by potentially life-threatening
type A thoracic aortic aneurysm dissection (TAAD). There
is growing evidence of genetic variation in genes known to
be critically important in the development of TAA, includ-
ing FBN1 encoding fibrillin 1, TGFBR1/2 encoding trans-
orming growth factor- receptors, and ACTA2 and
HY11, which encode smooth muscle -actin and myosin
eavy chain, respectively, that predispose humans to aortic
iseases (1). We recently reported that transgenic mice
ngineered to express human S100A12 in the aortic smooth
uscle develop thoracic aneurysms (2), similar to mouse
odels of Marfan syndrome (3). S100A12 is a proinflam-
atory protein that activates the receptor for advancedlycation end products (RAGE) (4) and accelerates atherosclerosis
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(5). Moreover, S100A12 gene
expression in human peripheral
blood cells is one of the most
predictive genes for obstructive
coronary artery disease (6), and
S100A12 is expressed in smooth
muscle and inflammatory cells in
ruptured coronary artery plaque
of victims of sudden cardiac
death (7), suggesting a critical
role of S100A12 in vascular dis-
ease and atherothrombosis. Al-
though the expansion of the aor-
tic wall occurs slowly and often is
asymptomatic clinically, dissec-
tion of the medial layer with
bleeding within and along the
aortic wall occurs suddenly and
leads to major complications, in-
cluding rupture, ischemia, and
arterial thrombosis with emboli-
zation, accounting for at least
16,000 deaths annually in the
United States (1,8). The precip-
itating mechanisms underlying
dissection are incompletely understood and include hemo-
dynamic factors, endothelial factors, as well as dysfunctional
smooth muscle cells (SMC). Moreover, inflammation and
the presence of inflammatory cells within the aortic media
recently were emphasized as potential mediator for dissec-
tions (8,9). Because S100A12 is a potent proinflammatory
and chemoattractant protein, and TAA develops in
S100A12 transgenic mice, we wished to examine S100A12
expression in human aortic diseases. We found strong
expression of S100A12 in inflammatory cells and in SMC in
all cases of thoracic aneurysms with type A dissection and in
approximately 25% of cases of clinically stable TAA. Fur-
thermore, studies on cultured human aortic smooth muscle
cells (HASMC) obtained from patients with TAA or
TAAD showed a direct role of S100A12 in mediating
apoptosis. Together, these data demonstrate that S100A12
is up-regulated in TAAD and may contribute to the
pathogenesis of TAAD by initiating apoptosis of SMC, at
least in part via increased oxidative stress.
Methods
The University of Chicago Medical Center Pathology
Tissue Bank was searched between 2007 and 2010, and 20
cases of elective TAA repair were chosen randomly. To
validate our findings from the initial 20 randomly chosen
patients, 30 additional patients with TAA or TAAD were
studied with either emergent surgery for type A aortic
dissections or elective surgery for large aneurysms (5.5
Abbreviations
and Acronyms
DNA  deoxyribonucleic
acid
EuroSCORE  European
System for Cardiac
Operative Risk Evaluation
HASMC  human aortic
smooth muscle cells
IgG  immunoglobulin G
LPS  lipopolysaccharide
MASMC  murine aortic
smooth muscle cells
MPO  myeloperoxidase
RAGE  receptor for
advanced glycation end
products
SMC  smooth muscle
cells
TAA  thoracic aortic
aneurysms
TAAD  thoracic aortic
aneurysm dissection
TNF  tumor necrosis
factorcm). All patients had no pre-operative diagnosis or knowncoronary artery diseases or peripheral artery disease. Retro-
spective data were collected by reviewing patient medical
records, and operative risk before surgery was calculated
using the additive and the logistic European System for
Cardiac Operative Risk Evaluation (EuroSCORE). Normal
control aortic tissue was obtained from heart donors (n  3,
2 men, age: 44  12 years), aortic valve replacement for
stenotic tricuspid aortic valve with normal aorta (n 2, 2 men,
age: 48  8 years), and elective left ventricular assist device
(n  1, woman, age: 32 years). Serial histological sections
were prepared from paraffin-embedded aortic tissue blocks
and were stained with hematoxylin and eosin, Verhoeff Van
Giessen, and Movat, and immunochemistry analyses were
carried out with staining with S100A12 immunoglobulin
G (IgG, Abcam 37657, Abcam Cambridge, United King-
dom), -myeloperoxidase (MPO) IgG (Abcam 9535, Ab-
cam, Cambridge, Massachusetts), and -smooth muscle actin
(Sigma-Aldrich). Staining for S100A12 was semiquantified by
2 blinded investigators (D.D., M.A.H.B.) as absent (0),
mild (1), moderate (2), or intense (3) in cells that
demonstrated either positive or negative results for MPO
staining. Loss of aortic medial elastic fibers was graded as 1
(trace), 2 (mild), 3 (moderate), and 4 (full-thickness loss), as
previously reported by Roberts et al. (10,11).
Aortic SMC. HASMCs were cultured from operatively
excised aortic tissue (bicuspid aortic valve: n  3, TGFBR1
mutation: n  2, FBN1 mutation: n  2, unknown cause:
 3), as previously described (2). Control HASMC were
btained from heart donors (n  3), aortic valve replace-
ent for stenotic tricuspid aortic valve with normal aorta
n  2), and elective left ventricular assist device (n  1).
urine aortic smooth muscle cells (MASMC) were ob-
ained from hemizygous S100A12 transgenic mice of the
57BL6/J strain previously generated (2) and from mice
ated with C57BL6/J mice lacking RAGE (RAGE/),
supplied by Dr. Ann Marie Schmidt (New York University,
New York, New York). Only cell cultures demonstrating
negative results for contaminating leukocytes (-CD45.2
ntibody from Pharmingen no. 559985 and -CD68 anti-
ody from Pharmingen no. 556059, BD Biosciences
harmingen, San Diego, California) were propagated.
MC characterized by staining for smooth muscle actin
Sigma-Aldrich) from passage 4–7 were used for experi-
ents. If indicated, soluble RAGE, the extra cellular ligand
inding domain of RAGE (20 g/ml, R&D Systems),
ovine serum albumin (20 g/ml, Sigma-Aldrich),  lipoic
cid (1 M, 10 M, and 100 M, AstraZeneca), or
iphenyleneiodonium (DPI) (1 and 10 M, Sigma-
Aldrich) was added before stimulation with lipopolysaccha-
ride (LPS) (100 ng/ml, Sigma-Aldrich), tumor necrosis
factor alpha (TNF) (10 ng/ml, Pierce, Rockford, Illinois),
or Fas IgG (CH 11, EMD Millipore). Where indicated,
HASMC were transfected with small hairpin RNA (shRNA)
encoding for S100A12 and control shRNA (SABiosciences)
using the lipofectamine method (Clontech). Transfected
HASMC were selected 3 days later by fluorescence-
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pressed in the shRNA plasmids before further analysis.
Immunoblotting was performed on whole cell lysate
(Pierce) for S100A12 (Abcam 37657), b-actin, caspase 3,
Fas (Cell Signaling Technology, Danvers, Massachusetts),
Fas ligand (Cell Signaling Technology, Beverly, Massachu-
setts), and deoxyribonucleic acid (DNA) fragmentation
factor A (DFFA, Millipore), and semiquantitative analysis
was performed using ImageQuant TL software (Amer-
sham/GE Healthcare, Little Chalfont, United Kingdom).
Quantitative reverse-transcriptase polymerase chain reac-
tion (RT-PCR) was performed from high-quality total
RNA (Qiagen) after transcription to complementary DNA
(cDNA, Qiagen whole transcriptome assay) using SYBR
GreenER (Invitrogen, Carlsbad, California) amplification
with an IQ5 cycler (Bio-Rad, Hercules, California). Path-
way focused microarray RT-PCR was purchased from
SABiosciences. Primers were designed on the primer bank
MGH library. Relative levels of gene expression were
calculated: relative mRNA expression  2exp (CT target
gene  CT housekeeping gene). Immunofluorescent as-
ays for caspase 3 (BioVision, Milpitas, California) were
nalyzed on a Fluostar Optima plate reader (BMG Labtech,
rtenberg, Germany). For immunofluorescence micros-
opy, SMC were grown on glass cover slips, fixed with 20%
ce cold methanol, or analyzed for apoptosis using a assay for
erminal deoxynucleotidyl transferase dUTP nick end label-
ng (TUNEL) from Roche, Applied Science, Cells were
maged by confocal laser microscopy (Zeiss 500 Meta), and
uorescent intensity was analyzed in 5 high-power fields, at
east in 200 cells.
The study and all procedures were carried out with the
pproval of the Chicago Institutional Review Board and the
nstitutional Animal Care and Use Committee.
tatistical analysis. Descriptive statistics (percentage,
ean, and SD), crude comparisons based on chi-square
tatistics, and plots were used to describe the patient cohort.
Patient CharacteristicsTable 1 Patient Characteristics
Nonurgent TAA (n  20)
1. Cohort (n  20)
Male, n (%) 11 (55)
Age (range), yrs 57 (19–82)
EuroSCORE 9.3 (4–16)
WBC 8.1
Creatine 1.2
S100A12 positive 7 cases
Histological results Dissection (n  4)
Necrotizing aortitis (n  2)
Atherosclerosis (n  1)
S100A12 negative 13 cases
Histological results Medial degeneration (n  12)
Dissection (n  1)
S100A12 was expressed in 7 of 20 elective TAA cases chosen randomly and was found in the aortic
with acute TAAD demonstrated positive stain results for S100A12 in the medial layer, and 4 of 16 patie
EuroSCORE  European System for Cardiac Operative Risk Evaluation; TAA  thoracic aortic aneurysmll continuous data are reported as mean  SD, and
discrete variables are summarized by percentage. All exper-
iments were performed in at least 3 replicates per group, and
all cell culture experiments were repeated 3 times. The
independent-sample t test and 1-way analysis of variance
ere used for mean comparisons between 2 or multiple
roups, respectively. The Spearman rank correlation,
-sided chi-square test for 2 independent proportions, and
isher exact test also were performed to describe association
etween different outcome variables. We applied the Bon-
erroni correction to the 0.05 significance level to adjust for
ultiple comparisons.
esults
100A12 protein is significantly up-regulated in human
horacic aortic type A dissection. We first studied
100A12 expression in aortic tissue collected from 20
atients undergoing elective repair for TAA (Table 1). All
atients had a computed tomography image of the chest or
n angiogram showing a TAA of at least 4.5 cm and were
eferred for nonurgent surgery. Of those 20 patients, 7 had
bicuspid aortic valve, 2 had Marfan syndrome, 1 had
amilial TAA, and 10 patients had no specific diagnosis
efore surgery. We found S100A12-positive cells within the
edial layer in 7 cases, and representative images are shown
n Figure 1. S100A12 expression was observed in necrotiz-
ng aortitis (Fig. 1E), in atherosclerosis (Fig. 1H), and in
ases with histological evidence of subacute dissection (Fig.
K), whereas we did not observe S100A12 expression in the
edial layer in the other 13 cases of TAA (Fig. 1B) or in
onaneurysmal control aortic tissue (n  5, not shown).
mportantly, all patients in this group underwent elective
nd nonurgent repair of TAA. Notably, the 7 patients with
100A12 expression in the aorta had a significantly in-
reased length of hospitalization after surgery, with a mean
uration of 24 days (range, 9 to 49 days) compared with a
Urgent TAAD (n  14) Nonurgent TAA >5.5 cm (n  16)
2. Cohort (n  30)
5 (35) 9 (56)
55 (34–74) 54 (22–65)
17.3 (9–21)* 9.1 (5–15)
12.4* 6.8
1.3 1.2
14 cases* 4 cases
Dissection (n  14) Dissection (n  2)
Medial degeneration (n  2)
0 cases 12 cases
Medial degeneration (n  10)
Dissection (n  2)
layer, localized to areas of chronic and subacute dissection, aortitis, or atherosclerosis. All patientsmedial
nts with large and elective TAA showed S100A12 stain in the medial layer. *p  0.0001.
s; TAAD  thoracic aortic aneurysm dissection; WBC  white blood cell.
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S100A12-negative TAA patients (p  0.04). The post-
operative complications we encountered included prolonged
ventilation resulting from respiratory failure (n  2) and
multiorgan failure with need for dialysis (n  1). One
patient died on post-operative day 15 of multiorgan failure
occurring after revision for aortic graft dehiscence in the
S100A12-positive group; this is compared with no deaths in
the S100A12-negative group. To account for pre-operative
comorbidities, we calculated the EuroSCORE, a widely
used score to predict mortality resulting from cardiac sur-
gery (12). We found no difference in the EuroSCORE
between the S100A12-positive and the S100A12-negative
cases (10.0 and 8.7, respectively, p  0.62) (Fig. 1N).
Moreover, there was also no difference in age between the 2
groups. This suggests that expression of S100A12 in aortic
tissue in TAA is a marker of post-operative complications
with increased length of hospital stay.
In the S100A12-positive cases, we found S100A12
mostly expressed in the medial aortic layer associated with
inflammatory changes or histological evidence of subacute
dissection (Figs. 1D to 1L). By contrast, in TAA cases
showing medial degeneration, but without histological evi-
dence of dissection, S100A12 was not expressed or only
minimally expressed; except in 1 of the 13 S100A12-
Figure 1 S100A12 Expression in Stable Thoracic Aortic Aneury
Photomicrographs showing histopathological results of 4 representative patients w
(B,E,H,K, and in higher magnification C,F,I,L) shows no S100A12 expression in C
m. Graphs showing quantification of (M) S100A12 expression in tissue, (N) calc
(O) age, (P) length of stay (LOS), and (Q) death of 20 patients undergoing electiv
neg  negative ; pos  positive; TGFR1  transforming growth factor, beta recenegative TAA cases, we found histological evidence ofchronic dissection. Therefore, to test directly the hypothesis
that S100A12 is a marker of aortic dissection, we selected
14 patients with from our histology archive in whom
TAAD was diagnosed prior undergoing urgent surgical
repair. As expected, these TAAD patients had higher
pre-operative EuroSCOREs (mean: 17.3, range: 9 to 21)
(Table 1), and on histological examination, all 14 cases had
S100A12-positive cells in the medial layer of the ascending
thoracic aorta. Costaining for MPO, a peroxidase enzyme
expressed in all myeloid cells and abundantly enriched in
neutrophil granulocytes, revealed S100A12 expression in
MPO-positive inflammatory cells and also in MPO-negative
SMC (Fig. 2). To account for factors possibly related to
disease severity, we selected 16 more cases of advanced
TAA with aneurysms exceeding 5.5 cm undergoing elective
and nonurgent repair of TAA. We found S100A12 expres-
sion in 4 cases (25%) of TAA of more than 5.5 cm,
compared with 100% in TAAD (p  0.0001). The
S100A12 expression in those cases of large TAA was
localized to a tear with dissecting split of the medial layer
(n  2), and in 2 cases, it was localized to medial
degeneration without dissection. The intensity of S100A12
stain overall was less in the clinically stable TAA cases,
compared with the cases with acute dissection. The speci-
ficity of the staining for S100A12 was verified by immuno-
A stained for hematoxylin and eosin (H&E) (A,D,G,J), and stained for S100A12
100A12 expression (brown) in the medial layer in F, I, and L. Scale bar 10
logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE),
urgent surgery for thoracic aortic aneurysms (TAAs). MFS  Marfan syndrome;
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further a possible association of S100A12 expression in
aneurysmal aortic tissue with other key processes of aortic
remodeling, we graded the integrity of aortic medial fibers.
The morphological features of elastic fibers serve as a good
marker of chronic aortic remodeling, such as replacement
with fibrous tissue and deposits of mucoid material, and are
easily discernible, and the grading of elastic fiber loss is
highly reproducible. This is in contrast to acute type A
dissection, where abnormal ascending aortic elastic fibers
uncommonly precede acute dissection (10,11). Online Figure 1
shows the frequency of elastic fiber degradation in elective
TAA with regard to S100A12 protein expression. For
neurysms smaller than 5.5 cm, intact or only minimal fiber
loss (grade 0 to 1) is more prevalent among S100A12-
negative aneurysms (61% vs. 0%, p  0.007), whereas
advanced elastolysis grade 3 or 4 is more prevalent among
S100A12-positive TAA (57% vs. 8%, p  0.015). This
elationship was not observed among larger TAAs, and there
Figure 2 S100A12 Expression in Thoracic Aortic Aneurysm Dis
(A) Costaining for S100A12 (brown) and myeloperoxidase (MPO, blue) showing S
MPO-positive cells (A2). (B, B1) Expression of S100A12 is most intense near the
tear. Scale bar  10 m. (D) Verification of S100A12 protein by immunoblot. Qua
thoracic aortic aneurysm dissection (TAAD) (n  14) and stable TAA of more thanas no difference in high-grade elastolysis in cases of largeTAA of more than 5.5 cm with and without S100A12
expression (50% and 33%, respectively, p  0.55). These data
suggest that S100A12 expression in aneurysmal aorta is asso-
ciated with proteolysis of elastic fibers, because all S100A12-
positive TAAs had evidence of grade 2 or higher elastic fiber
degradation.
Moreover, expression of activated caspase 3, an enzyme
known to play a central role in the execution phase of cell
apoptosis, also was present in all TAAD tissue and colocal-
ized with S100A12 to the area near the dissection tear in the
tunica media. Caspase 3 was not detected in S100A12-
negative cases (Fig. 2).
Furthermore, we examined cultured aortic SMC and
found increased mRNA and protein expression of cell death
receptor Fas and Fas ligand in the cell lines that also express
S100A12 (3.5-fold increase in Fas protein and 2.6-fold
increase in Fas ligand protein, p 0.01) (Online Fig. 2). As
xpected, we found enhanced mRNA for several members
f the transforming growth factor  signaling pathways in
on
2 expression in MPO-negative smooth muscle cells (A1) and in inflammatory
ction tear and colocalizes to (C, C1) caspase 3-positive cells near the dissection
tion of (E) S100A12 and (F) caspase 3 expression in patients with unstable
(n  16). Abbreviation as in Figure 1.secti
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S100A12 expression in the different TAA-HASMC lines
(Online Fig. 2).
Reduction of endogenous S100A12 in cultured HASMC
attenuates apoptosis. The relationship of S100A12 to
markers of apoptosis was studied in cultured HASMC
harvested from patients undergoing surgical repair for TAA
or TAAD and in control HASMC from patients undergo-
ing cardiac surgery without TAA or TAAD. We found
variable expression of S100A12 in HASMC from TAA or
TAAD by immunoblotting and no expression of S100A12
in control HASMC (data not shown). Three independent
HASMC lines with endogenous S100A12 expression were
studied; one carried a known mutation in the FBN1 gene
(R529X) harvested from a patient with Marfan syndrome,
and one cell line carried a mutation in the TGFBR1 gene
(977A¡C, K326T) from a patient with familial TAA, and
a third TAA-HASMC line was without specific genetic
diagnosis. HASMC were transfected transiently with inter-
fering short hairpin RNA (shRNA) to knock down endog-
enous S100A12 or with control shRNA. After isolation of
the cells positive for green-fluorescent protein (GFP) by
flow cytometry, we confirmed complete absence of
S100A12 in the HASMC transfected with shRNA-
S100A12 and endogenous S100A12 expression in HASMC
transfected with control shRNA (Fig. 3). We next examined
gene expression in the FBN1R529X HASMC endogenously
xpressing S100A12 (shRNA-control transfected cells) and
ompared this with FBN1R529X HASMC with reduction of
100A12 (shRNA-S100A12 transfected cells) using
athway-focused RT-PCR microarrays for apoptosis and
nflammation (SABiosciences). We identified broad down-
egulation of apoptosis- and inflammation-regulating genes.
f the 84 genes present on the microarray plate, 23 genes
ere more than 2-fold and 49 genes were 2-fold down-
egulated on the apoptosis array, and 19 genes were more
han 2-fold and 56 genes were 2-fold down-regulated on
he inflammation microarray (Online Table 1). Because we
ound strong reduction in Fas, caspase 3, and DFFA, we
ext examined these genes using quantitative RT-PCR in
ndependent complementary DNA samples of the 3
100A12-expressing HASMC lines. As shown in Figure
D, reduction of S100A12 abolished mRNA for Fas,
aspase 3, and DNA-fragmentation factor (p  0.0001).
oreover, reduction of S100A12 suppressed protein ex-
ression for Fas and cleaved caspase 3 and DNA- fragmen-
ation factor by 40% to 60% in S100A12-expressing
ASMC (p  0.02), but had no effect on S10012-negative
ASMC (Figs. 3E and 3F). To confirm a critical role of
100A12 on caspase 3 activation, we stimulated S100A12-
xpressing HASMC with apoptosis-initiating monoclonal
as IgG and observed a 2.8-fold increase in active caspase 3
sing an immunofluorescent active caspase 3 assay. shRNA
eduction of S100A12 reduced Fas-IgG–stimulated active
aspase 3 by 80% (p 0.001) (Fig. 3G). These data suggest chat S100A12 is a critical nodal point in many apoptosis-
nd inflammation-regulating genes.
100A12 is induced in HASMC by cytokines, and
nockdown of S100A12 attenuates cytokine-induced
ctivation of caspase 3 in a partial RAGE-dependent
anner. We previously showed that LPS induces
100A12 in HASMC in agreement with other studies that
howed induction of S100A12 in response to cytokine
timulation (13,14). Moreover, studies of the S100A12 gene
ndicated that CCAAT/enhancer-binding protein beta and
rotein kinase C are critical regulators of transcription in
esponse to LPS (15). As shown in Figure 4A, stimulation
ith low-dose LPS or with the distinct cytokine TNF
induced S100A12 in normal HASMC. PCR amplification
detected complementary DNA for Fas, caspase 3, and
DFFA in both control HASMC (bovine serum albumin)
and in cytokine-treated HASMC (LPS or TNF), with
significantly higher gene expression for Fas, caspase 3, and
TNF in cytokine-treated HASMC compared with control
HASMC (p  0.05 for each gene). Importantly, cotreatment
with shRNA-S100A12 attenuated cytokine-induced gene ex-
pression for Fas, caspase 3, and DFFA by 70% to 90% (p 
0.01 for each gene), whereas control shRNA had no effect on
cytokine-induced up-regulation of apoptosis-controlling genes
(Fig. 4B). Quantification of active caspase 3 showed a 1.6-fold
increase in LPS-treated cells and a 1.9-fold increase in TNF-
treated cells compared with baseline; this was attenuated in
HASMC cotreated with shRNA-S100A12 by 74% and 65%,
respectively (p  0.05) (Fig. 4C).
To study potential mechanisms involved in S100A12-
mediated apoptosis, we used MASMC. Briefly, transgenic mice
with expression of human S100A12 in aortic smooth muscle
were generated previously (2) and then crossed with mice
lacking RAGE (16). We previously reported that transgenic
S100A12-MASMC had higher levels of oxidative stress and
interleukin-6 secretion, among other changes, characteristic of
a phenotypic switch from a contractile to a synthetic phe-
notype, and these changes were attenuated by cotreatment
with soluble RAGE (2), the S100A12 ligand-binding
domain of RAGE, thus preventing activation of cell surface
RAGE. We then expanded these findings by measuring
activated caspase 3 in S100A12-expressing MASMC and
found a slight increase compared with wild-type MASMC
(1.3-fold, p  0.04). Importantly, on stimulation with
low-dose LPS (100 ng/ml) or low-dose TNF (20 ng/ml),
the S100A12-MASMC showed strong activation of caspase
3 (4- and 2.9-fold, respectively) compared with a 1.3- and
1.4-fold increase in wild-type MASMC (Fig. 5A). More-
over, cytokine stimulation caused enhanced DNA fragmen-
tation as visualized by TUNEL staining in S100A12-
MASMC, but only minimally in wild type-MASMC at the
studied concentrations for LPS and TNF (15% vs. 7% and
2% vs. 7%, respectively, p  0.01) (Fig. 5B). Most
mportantly, MASMC lacking RAGE were protected from the
ynergistic effects of S100A12 and LPS or TNF stimulation on
aspase 3 activation and cell apoptosis. Activated caspase 3 was
781JACC Vol. 60, No. 8, 2012 Das et al.
August 21, 2012:775–85 Dissection Risk for Thoracic Aortic Aneurysmreduced in cytokine-stimulated S100A12- MASMC by 58% and
52% in cells lacking RAGE compared with S100A12- MASMC
with intact RAGE signaling (p  0.01) (Fig. 5A). This was
paralleled with a significant reduction of TUNEL-positive
MASMC (Fig. 5B). Together, we found that smooth
muscle targeted forced expression of human S100A12 in
Figure 3 ShRNA-Mediated Reduction of Endogenous S100A12
(A) Flow cytometry for expression of green-fluorescent protein (GFP) was used to i
or shRNA-control. (B) shRNA-S100A12 (lane 2), but not shRNA-control (lane 4), ab
and inflammation-regulating genes after reduction of S100A12 in HASMC-Fbn1R52
microarray (complete data shown in Online Table 1). S100A12 expressing HASMC
analyzed for (D) gene expression for Fas, caspase (casp.) 3, and DNA fragmentat
Quantification for capase 3 using immunofluorescent activity assay. *p  0.0001
DNA fragmentation factor A; GAPDH  glyceraldehyde-3-phosphate; dehydrogenas
nucleic acid; shRNA  short hairpin RNA; shRNA  short hairpin RNA; TRAIL  TNMASMC markedly enhanced cytokine-induced apoptosis,and this was dependent on RAGE, the cell surface receptor
for S100/calgranulins endogenously expressed on smooth
muscle cells.
Given the importance of reactive oxygen species to
inflammation, cell death, and apoptosis, we probed oxida-
tive stress-related changes. We found an increase in oxi-
man Aortic Smooth Muscle Cells Attenuates Apoptosis
transfected human aortic smooth muscle cells (HASMCs) with shRNA-S100A12
s S100A12 protein in HASMCs. (C) Changes in gene expression of apoptosis
ed by pathway focused reverse-transcriptase polymerase chain reaction (RT-PCR)
(n  3) were transfected with shRNA and, after selection by flow cytometry, were
tor A (DFFA), and for (E, F) protein content of Fas, caspase 3, and DFFA. (G)
 bovine serum albumin; cDNA  complementary deoxyribonucleic acid; DFFA 
 green fluorescent protein; IgG  immunoglobulin G; mRNA  messenger ribo-
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60% of all nuclei staining positive for this marker of oxidative
damage to the DNA in S100A12 transgenic MASMC, com-
pared with a less than 2% baseline in wild-type MASMC (p 
0.001) (Fig. 5C). S100A12-MASMC lacking RAGE had re-
duced significantly the number of oxidized nuclei (25%, p 0.01)
ompared with S100A12-MASMC with intact RAGE sig-
aling, confirming that the pro-oxidative effect of S100A12
s mediated, at least in part, by RAGE. Treatment with
Figure 4 Knockdown of S100A12 in HASMC Attenuates Cytok
(A) S100A12 is induced in control HASMCs by lipopolysaccharide (100 ng/ml for 1
(B) Gene expression for Fas, caspase 3, and DFFA measured by quantitative reve
using immunofluorescent activity assay. LPS  lipopolysaccharide; other abbreviat
Figure 5 S100A12-Mediated Apoptosis in Smooth Muscle Cells
by Receptor for Advanced Glycation End Products and
(A to C) Murine aortic smooth muscle cells (MASMCs) from S100A12 and wild-typ
(RAGE/) and deleted RAGE (RAGE/) were treated as indicated with control (b
(D to F) S100A12-expressing HASMC and control HASMC were treated as indicate
was measured using (A and D) an immunofluorescence assay for active caspase
oxidized DNA stained with -8-oxo-dG IgG and (C and F) indexed to total number o
HASMC. Abbreviations as in Figures 3 and 4.DPI, an inhibitor of the nicotinamide adenine dinucleotide
phosphate-oxidase NADPH oxidase also attenuated DNA
oxidation, even in cells lacking RAGE (12% and 25%, p 
.04). These data suggest that oxidative stress in cultured
mooth muscle cells is a critical downstream effect of
100A12 mediated in large part by RAGE and by
ADPH-oxidase. Therefore, we tested the effects of anti-
xidant compounds on apoptosis markers in HASMC with
ndogenous S100A12 expression (harvested from TAA or
duced Apoptosis
e 3 and 4) and tumor necrosis factor (TNF)- (20 ng/ml for 16 h, lanes 5 and 6).
nscription PCR in HASMC treated as indicated. (C) Quantification for capase 3
s in Figure 3.
ediated
ative Stress
e with intact receptor for advanced glycation end products (RAGE) signaling
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nd E) TUNEL assay–determined percent of apoptotic nuclei, and (F) nuclei with
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August 21, 2012:775–85 Dissection Risk for Thoracic Aortic AneurysmTAAD cases) and in control HASMC without S100A12
expression. As shown in Figures 5D to 5F, pre-treatment
with -lipoic acid or DPI reduced active caspase 3, the
poptosis index determined by TUNEL assay, and reduced
he index for cells with oxidized DNA in a dose-dependent
anner.
iscussion
n inflammatory component was identified previously in
AA and TAAD, composed primarily of T cells and
acrophages (9). Our study demonstrates that S100A12, a
ytokine-like protein with proinflammatory signaling, is
ighly enriched in myeloid and in SMC in type A aortic
issection. On the basis of our cell culture data and the
nown pathological effects of S100A12 on smooth muscle
ells, we speculate that S100A12 is highly pathogenic in
AA and may predispose patients to aortic dissection.
100A12 is also known as calgranulin C or EN-RAGE
extracellular newly identified RAGE binding protein) be-
ause it activates pattern recognition receptor RAGE (4)
nd is likely also to activate Toll-like receptor 4, because this
as shown recently for the homolog S100A8/9 (17). More-
ver, S100 proteins are expressed endogenously in myeloid
ells and at high levels in neutrophil granulocytes and are
mplicated in the antibacterial and antifungal defense (18)
y activating the p67phox/NADPH-oxidase system to initi-
ate a respiratory burst in phagocytes (19). Similar to its
endogenous role in phagocytes, our laboratory recently
showed binding of S100A12 to NADPH-oxidase subunit
Nox-1 in vascular smooth muscle cells (5), and importantly,
Nox-1 inhibition attenuated S100A12-mediated dysfunc-
tion of aortic SMC (20).
Our laboratory recently showed a proapoptotic function
of S100A12 with increased expression of FAS, caspase 10,
and caspase 3 in human airway SMC (21) and thereby
extended previous studies showing that excess amounts of
S100A8/9 induce apoptosis and cell death in a variety of cell
types (22,23). Moreover, Boyd et al. (24) found a 40-fold
increase in S100A8/9 mRNA in cardiomyocytes in a mouse
model of sepsis, and S100B was up-regulated in ischemic
cardiomyocytes (25). Importantly, in both studies, up-
regulation of S100 proteins was associated with increased
cell death and tissue damage that was attenuated by inter-
ruption of RAGE signaling. Our studies presented here
demonstrate that down-regulation of the ligand S100A12
attenuates cell death of SMC with pathological endogenous
expression of S100A12 and in SMC with cytokine-induced
expression of S100A12. These findings support the hypoth-
esis that S100A12 is an important regulator of cell survival
and cell death.
S100/calgranulins are involved in the regulation of nu-
merous intracellular activities, such as protein phosphoryla-
tion, enzyme activities, cell proliferation and differentiation,
cytoskeletal rearrangement and membrane organization, protec-
tion from oxidative stress, and regulation of intracellular Ca2homeostasis, and have been implicated in intercellular regu-
lation of chemotaxis, phagocytosis, and immunoregulation.
Therefore, the specificity for S100/calgranulin-mediated
effects likely depends on the tissue distribution and cell type.
This view is supported by recent findings in mice lacking
S100A9 in which constitutive deletion of murine S100A9 in
apolipoprotein E-deficient mice attenuated atherosclerosis
(26), whereas the lack of S100A9 in bone marrow–derived
cells did not attenuate atherosclerosis in low-density lipo-
protein receptor–deficient mice (27). Therefore, patholog-
ical expression of S100/calgranulins within the vasculature
may be an important accelerator of vascular disease, partic-
ularly because S100A12 is not present in normal vascular
tissue, but is highly up-regulated in smooth muscle cells of
diseased blood vessels, such as in human ruptured coronary
artery plaques (7), in human atherosclerosis (5) and, as
shown in this study, also in type A aortic dissections and, to
a lesser degree, in clinically stable TAA. It is intriguing that
TAA and TAAD are such focal diseases, and because there
is no access to distal vascular tissue other than the surgically
removed aneurysmal tissue in a given patient with TAA or
TAAD, we cannot exclude the possibility that S100A12
could be expressed in other vascular beds beyond the
aneurysmal thoracic aorta in those patients with TAA or
TAAD. It is interesting to note that S100A12 expression in
explanted SMC persists over several cell culture passages,
and this finding deserves further study. We speculate that
epigenetic changes occurring within the S100 gene cluster
may control S100 protein expression. This view is supported
by the presence of several CpG islands within the S100 gene
cluster and within the first intron of the S100A12 gene (28).
Therefore, methylation and demethylation of regulatory
DNA may explain the cell-specific expression of S100
proteins, which frequently is up-regulated or down-
regulated in various pathological states, including cancer
and vascular diseases.
S100A12 is more than an inflammatory biomarker. It causes
dysfunction of vascular smooth muscle with an increase in
matrix metalloproteinase-2 protein, interleukin-6, trans-
forming growth factor- signaling, and reduction of con-
tractile fibers leading to the development of thoracic aortic
aneurysms in transgenic mice expressing human S100A12
driven by the smooth muscle 22- promoter (2), demon-
strating a clear pathological effect of S100A12 in vascular
smooth muscle. S100 proteins and other ligands to RAGE
and Toll-like receptors, such as HMGB1 protein, previ-
ously were implicated in the process of sterile inflammation
associated with dying cells (29). Our report for the first time
shows that knockdown of S100A12 attenuates many
apoptosis- and inflammation-regulating genes, including
Fas-mediated apoptosis pathways. One interesting finding
in our study was the strong attenuation of inflammasome-
associated pathways, including PYCARD and caspase 1, after
reducing S100A12. Caspase 1 is activated in response to
multiple stimuli, but after being activated, results in a con-
served program of cell death referred to as pyroptosis (30).
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molecules are good candidate molecules to activate caspase 1,
and further exploration of these pathways may shed light on
the intracellular function of S100/calgranulins.
The proapoptotic function of S100A12 is mediated, at
least in part, by its cell surface receptor RAGE, which is
expressed in many cells, including SMC, endothelial cells,
and inflammatory cells (31). There is mounting evidence of
RAGE being a disease amplifier for initiation and progres-
sion of vascular diseases (reviewed in Yan et al. [32]),
including aortic aneurysms (33). RAGE-mediated cell per-
turbation is at least in part dependent on redox-sensitive
signals such as the translocation of redox-sensitive nuclear
factor  B, which, for example, is attenuated in stimulated
endothelial cells by pre-treatment with antioxidant  lipoic
acid (34). Using  lipoic acid and DPI, we showed marked
nhibition of S100A12-mediated cell death. This is in
greement with a recent study by Kim et al. (35) demon-
trating the ability of  lipoic acid to reduce vascular smooth
muscle cell apoptosis by restoring intracellular redox status.
Indeed, oxidative stress plays a key role in the pathogenesis
of thoracic aortic dissections, as recently demonstrated by
several studies. For example, Liao et al. (36) used compar-
ative proteomics and identified 126 proteins differentially
expressed in the aortic media of patients with dissections
and with normal aortas. Interestingly, increased lipid per-
oxidation and a more than 50% reduction in superoxide
dismutase in aortic type A dissections was one of the most
important changes noted in this study.
The coexistence of inflammatory cells with markers of
apoptotic vascular cell death in the media of ascending
aortas with aneurysms and type A dissection was noted
previously by several investigators (8,9). However, it re-
mains unknown whether apoptosis of medial smooth mus-
cle cells occurs before dissection as a primary event leading
to weakening and rupture of the aortic wall, or alternatively,
as suggested by Roberts et al. (11), the intraluminal arterial
pressure in the false luminal channel compresses the adja-
cent media and induces cell death after, not before, acute
dissection.
Conclusions
Critical pathways involved in TAA and progression to
TAAD include immunological processes, such as T-cell and
natural killer cell pathways, oxidative stress, depletion of
vascular smooth muscle through the process of apoptosis,
and the destruction of the extracellular matrix by matrix
metalloproteinases (1). Here we showed evidence that
S100A12 is highly expressed in the medial layer in acute
type A aortic dissection. Because all samples from TAAD
cases expressed S100A12 regardless of the heterogeneity
present in this sample group, we speculate that S100A12
expression in aortic smooth muscle is a common response to
multifactorial injury. This is supported by our findings in
clinically stable TAA, in which we found S100A12 expres-sion in approximately 25%, most commonly associated with
histological evidence of dissection. Alternatively, it is pos-
sible that S100A12 is a marker of the inflammatory changes
that occur in the aortic wall after acute or chronic dissection,
rather than being a predisposing factor for dissection. This
underscores the complex biology of aortic disease, and
histological examination of aneurysmal or dissected aortic
tissue is inevitably unlikely to determine the temporal
relationship between vascular inflammation and aortic dis-
section. The mechanisms by which S100A12 becomes
up-regulated in human aortic diseases is not understood
completely, but it likely is in response to various inflamma-
tory signals, because we demonstrated a robust induction of
S100A12 in normal human aortic smooth muscle cells on
treatment with LPS and TNF. Further studies using aortic
issue, rather than in cultured aortic smooth muscle cells
rom patients with thoracic aneurysms, are needed to examine
he impact of S100A12 on key vascular proteins, such as
brillin, collagen, and others. One limitation of our study is the
mall number of patients and the heterogeneity within the
ontrol group. Importantly, reduction of S100A12 attenuates
any apoptosis- and inflammation-regulating genes in
ASMC with endogenous S100A12 expression and in
ytokine-primed MASMC with forced expression of human
100A12. S100A12-mediated cell death is, at least in part,
ependent on RAGE-generated and NADPH-oxidase–
enerated oxidative stress, because apoptosis is attenuated in
mooth muscle cells lacking RAGE and in HASMC treated
ith the antioxidants  lipoic acid and DPI.
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